Eletriptan (brand name Relpax) is available in 20 mg and 40 mg tablets, with 40 mg being the standard recommended starting dose for an acute migraine attack. A second 40 mg tablet can be taken if the headache returns or does not fully resolve, bringing the maximum single-day dose to 80 mg. The distinction between these dose levels matters more than it might seem, because the jump from 40 mg to 80 mg produces real differences in how quickly and completely the migraine resolves, and the research on eletriptan dosing is unusually rich for a triptan.
What the Standard Doses Look Like in Practice
Three dose levels have been studied in clinical trials: 20 mg, 40 mg, and 80 mg. In most countries, the approved starting dose is 40 mg taken as soon as you recognize you are having a migraine. If the headache comes back or is not adequately relieved after two hours, a second 40 mg dose is allowed, but the total for any 24-hour period should not exceed 80 mg. Some prescribers write for 80 mg as a single dose in patients who consistently find 40 mg insufficient, though labeling in several markets treats 80 mg as the redosing ceiling rather than a first-line single dose.
The 20 mg dose exists in some markets and has been studied, but it occupies a niche role. It works significantly better than placebo, yet falls noticeably behind 40 mg and 80 mg on most outcomes. A Cochrane review of eletriptan trials found that the number of people you would need to treat with 20 mg to get one additional person pain-free at two hours was about 10, compared with about 4 for the 40 mg dose and roughly 3.7 for 80 mg.1Cochrane Database of Systematic Reviews. Eletriptan for acute migraine That gap is substantial enough that most clinicians skip 20 mg entirely and start at 40 mg.
Does a Higher Dose Actually Work Better?
Yes, and the evidence is consistent across populations. In a large placebo-controlled trial, headache relief at two hours was reported by about 62% of patients on 40 mg and 65% on 80 mg, versus 19% on placebo. Complete pain freedom followed a similar pattern: roughly 32% at 40 mg and 34% at 80 mg, compared with just 3% on placebo.2PubMed. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks The difference between 40 mg and 80 mg looks modest in those numbers, but the gap widens when you look at speed of onset and 24-hour sustained relief rather than just the two-hour snapshot.
A head-to-head comparison against sumatriptan showed the dose-response curve more dramatically. At two hours, headache response rates were about 54% for eletriptan 20 mg, 65% for 40 mg, and 77% for 80 mg, all against a 24% placebo rate. The 80 mg dose was also the only one that significantly outperformed sumatriptan 100 mg in that trial.3PubMed. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan A Japanese trial confirmed the same stepwise pattern, with response rates climbing from 64% at 20 mg to 67% at 40 mg and 76% at 80 mg, and a statistically significant dose-response trend for both headache relief and pain-free rates.4PubMed. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs
The trade-off is that side effects also increase with dose, though most remain mild: dizziness, nausea, drowsiness, and a sensation of tightness in the chest or throat that is characteristic of triptans as a class. In the trials, no deaths or treatment discontinuations were attributed to eletriptan at any dose, and the comprehensive safety review found the drug well tolerated regardless of age or gender across both short- and long-term use.5PubMed. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review
Treating Early Makes a Bigger Difference Than You Might Expect
One of the most practical findings in the eletriptan literature has nothing to do with choosing between 40 mg and 80 mg. It is about when you swallow the pill. A study that pooled data across multiple trials found that patients who took eletriptan 40 mg while the pain was still mild achieved a two-hour pain-free rate of 68%, versus 25% on placebo. What made this striking was the finding that pain intensity at the time of dosing influenced the outcome more than how early in the attack the dose was taken relative to headache onset.6PubMed. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing
In plain terms, the clock that matters is not “minutes since the headache started” but “how bad is it right now.” A person who takes eletriptan 40 mg at mild pain gets results that rival what 80 mg achieves in moderate-to-severe attacks. This is one reason neurologists stress not waiting to see if the headache will resolve on its own. Treating while pain is still manageable can effectively turn a standard 40 mg dose into a high-performing one.
How Eletriptan Stacks Up Against Other Triptans
Eletriptan is not just another interchangeable member of the triptan family. A network meta-analysis that compared all oral triptans head to head found that eletriptan consistently produced the highest treatment effects. For the two-hour endpoints, it was significantly superior to sumatriptan, almotriptan, naratriptan, and frovatriptan. At 24 hours, it also outperformed sumatriptan, rizatriptan, almotriptan, and naratriptan. The probability that eletriptan was the single best triptan for producing a pain-free response at two hours was estimated at 68%.7PubMed. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis
A model-based meta-analysis that adjusted for the encapsulation effect (a methodological issue in triptan trials where over-encapsulation of the comparator drug can slightly reduce its apparent efficacy) still found a significant clinical benefit of eletriptan 40 mg over sumatriptan 100 mg. The advantage peaked at about 1.5 to 2 hours after dosing, with roughly 9% more patients achieving pain relief and about 7% more becoming pain-free on eletriptan.8PubMed. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain–results of a model-based meta-analysis that accounts for encapsulation A broader comparison across all oral triptans found that the mean therapeutic gain (the percentage-point improvement over placebo) was 37% for eletriptan 40 mg and 42% for eletriptan 80 mg, compared with 32% for oral sumatriptan 100 mg and 37% for rizatriptan 10 mg.9PubMed. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy
These are not dramatic differences in absolute terms, but for someone who has tried sumatriptan and found it almost-but-not-quite effective, eletriptan at the same or a higher dose tier is the most evidence-backed next step within the triptan class.
Speed of Absorption and How Long It Lasts
Eletriptan reaches peak blood levels quickly, with a median time to maximum concentration of about 1 to 1.25 hours after swallowing the tablet. Its elimination half-life ranges from roughly 3.6 to 7 hours, which places it in the middle of the triptan family, neither the fastest to wear off nor the longest-acting.10PubMed. The pharmacokinetics and safety of single escalating oral doses of eletriptan The drug shows linear pharmacokinetics across the therapeutic dose range, meaning that doubling the dose roughly doubles the drug exposure. That linearity is part of why the dose-response relationship described above is so clean and predictable.
One practical implication of the relatively fast absorption is that food has only a modest effect on how the drug behaves. Taking eletriptan with a meal may slightly delay peak levels but does not meaningfully reduce total absorption. For someone in the middle of a migraine and not inclined to eat, taking the tablet on an empty stomach is fine and may produce slightly faster relief.
Drug Interactions That Can Effectively Raise Your Dose
Eletriptan is broken down primarily by the CYP3A4 enzyme in the liver. Any drug that strongly inhibits CYP3A4 can slow eletriptan’s metabolism, causing blood levels to climb well beyond what the dose would normally produce. In a pharmacokinetic study, co-administration with ketoconazole (a potent CYP3A4 inhibitor) increased eletriptan’s total drug exposure more than threefold, from about 24 to 81 ng·h/mL, while also raising peak concentration from 32 to 40 ng/mL.11PubMed. Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes
That kind of increase means a person taking 40 mg of eletriptan alongside a strong CYP3A4 inhibitor could end up with drug exposure comparable to a much higher dose. Prescribing guidelines accordingly warn against using eletriptan within 72 hours of strong CYP3A4 inhibitors. Common culprits include:
- Antifungals: ketoconazole, itraconazole
- Antibiotics: clarithromycin, erythromycin (to a lesser degree)
- HIV protease inhibitors: ritonavir, nelfinavir
Moderate CYP3A4 inhibitors like fluconazole or grapefruit juice are less of a concern but can still nudge levels upward. If you take any of these medications regularly, your prescriber will likely either choose a different triptan or adjust the eletriptan dose downward.
Cardiovascular Safety and Who Should Not Take Eletriptan
All triptans narrow blood vessels, which is part of how they relieve migraine. The concern has always been that this vasoconstriction could affect coronary arteries in people with underlying heart disease. A dedicated study using intravenous eletriptan at plasma levels equivalent to three to five times the peak concentration of an 80 mg oral dose found only modest coronary artery narrowing, roughly equivalent to what a standard dose of sumatriptan produces, and no cases of clinically significant vasoconstriction were observed.12PubMed. Effect of high-dose intravenous eletriptan on coronary artery diameter That is reassuring for the general migraine population, which tends to be younger and cardiovascularly healthy.
The flip side is that eletriptan, like all triptans, is contraindicated in people with established coronary artery disease, uncontrolled high blood pressure, or a history of stroke. A case report described a 53-year-old man with a history of atrial fibrillation and non-obstructive coronary artery disease who suffered a heart attack hours after taking eletriptan.13PubMed. Myocardial infarction after taking eletriptan That is a single case, but it underscores why the cardiovascular screening questions your doctor asks before prescribing a triptan are not just box-checking. If you have risk factors for heart disease, especially a combination of them, the decision to use eletriptan needs to be explicit and informed rather than automatic.
The chest tightness that some people experience after taking any triptan is usually not cardiac in origin. It is thought to involve serotonin receptors in the esophagus or chest wall muscles. Still, a person experiencing this for the first time should mention it to their doctor, particularly if it is severe or accompanied by shortness of breath.
Headache Recurrence After the Dose Wears Off
One frustrating feature of triptans is that the migraine can come back once the drug clears. Eletriptan’s recurrence rates have been directly compared with sumatriptan’s. In a comparative trial, headache recurrence within 24 hours of dosing was about 34% for eletriptan 40 mg and 32% for eletriptan 80 mg, similar to the 33% seen with sumatriptan 100 mg.14International Journal of Clinical Practice. PHARMACOLOGY AND EFFICACY OF ELETRIPTAN FOR THE TREATMENT OF MIGRAINE ATTACKS So roughly one in three people who get initial relief will see the headache return within a day, regardless of which dose they used.
When recurrence happens, taking a second dose of eletriptan 40 mg (provided you have not already reached 80 mg for the day) is the standard approach. Some clinicians also recommend pairing the triptan with a long-acting anti-inflammatory like naproxen to help bridge the gap as eletriptan clears the system. Using multiple acute migraine strategies together or switching between them is a recognized tactic for improving overall response rates.15Wolters Kluwer / Continuum. Acute Treatment of Migraine
A word of caution: using any acute migraine medication, including eletriptan, more than about 10 days per month risks triggering medication-overuse headache, a rebound cycle where the treatment itself starts perpetuating chronic daily headaches. If you find yourself reaching for eletriptan that frequently, it is a signal to talk with your doctor about preventive therapy rather than continuing to escalate acute treatment.
Eletriptan in Adolescents
The story in younger patients is surprisingly different from adults. A double-blind trial of eletriptan 40 mg in adolescents found no significant advantage over placebo for the primary endpoint of headache response at two hours: 57% responded on eletriptan and 57% on placebo. However, eletriptan did reduce headache recurrence within 24 hours (11% versus 25%) and showed significant advantages on sustained headache response and sustained pain-free rates in post hoc analyses.16PubMed. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial
This pattern of failing the primary endpoint while succeeding on secondary measures is common in adolescent migraine trials and has bedeviled the field for years. A systematic analysis found that among five triptans tested in adolescents, only almotriptan demonstrated clear efficacy, while eletriptan, sumatriptan, rizatriptan, and zolmitriptan all failed their primary endpoints.17JAMA Pediatrics. Migraine Therapeutics in Adolescents: A Systematic Analysis and Historic Perspectives of Triptan Trials in Adolescents The problem is widely attributed to the unusually high placebo response rates seen in adolescent migraine trials, which can exceed 50% and make it nearly impossible for an active drug to show statistical separation. It does not necessarily mean eletriptan is ineffective in teenagers, but the evidence base is weaker than in adults, and prescribing in this age group tends to be off-label.
When 40 mg Is Not Enough but 80 mg Feels Like a Lot
A common situation is the patient who gets partial but incomplete relief from 40 mg. Maybe the headache drops from severe to mild, or it resolves but comes back four hours later. The question becomes whether to take a second 40 mg tablet for that same attack, switch to a single 80 mg tablet for future attacks, or try a completely different approach.
The trial data suggest that the benefit of going from 40 mg to 80 mg is real but incremental. In the direct comparison trial, the pain-free rate at two hours was 29% for 40 mg and 37% for 80 mg.18PubMed. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan That is a meaningful difference for the individual: about one in every twelve or thirteen patients who would not have been pain-free at 40 mg will be at 80 mg. If you tolerate 40 mg well and find it almost adequate, trying 80 mg as a single dose (if your prescriber agrees) is a reasonable next move before abandoning eletriptan entirely.
The other practical lever, treating at the first sign of mild pain, can be equally or more powerful than increasing the dose. Combining early treatment with the 40 mg dose gives results that approach what late treatment at 80 mg delivers, with fewer side effects. If you have been waiting until the headache is fully established before reaching for the pill, moving the timing earlier may accomplish more than increasing the milligrams.
For patients on CYP3A4 inhibitors, where the effective blood levels of any given dose are already elevated, dose increases should be approached with extra caution. The three-fold rise in drug exposure seen with strong inhibitors means that a nominal 40 mg dose is already behaving more like a 120 mg dose in terms of systemic exposure, well beyond what the clinical trials studied.